Advertisement

Apoptosis

, Volume 6, Issue 1–2, pp 57–68 | Cite as

Novel vitamin K-dependent pathways regulating cell survival

  • S. P. Saxena
  • E. D. Israels
  • L. G. Israels
Article

Abstract

Historically, the vitamin K1-dependent proteins have been associated primarily with blood coagulation and secondarily with bone formation. Recent identification of K1-dependent proteins as specific ligands for the receptor tyrosine kinases (RTKs) that can stimulate cell replication and transformation and participate in cell survival highlighted a previously unrecognized and potentially important role for vitamin K1 in cell signaling. Growing evidence suggests that most normal and tumor cells possess an active K1-dependent γ-carboxylation mechanism necessary for the production of γ-carboxyglutamic acid (Gla)-containing proteins. Gla residues in proteins facilitate calcium-dependent protein/phospholipid interaction. Recent studies demonstrating the potentially positive effects of a vitamin K-dependent receptor:ligand system on cell growth and survival in general and the effects of the overexpression of these RTKs on malignant cell survival provide a new perspective on the role of vitamin K1, its dependent protein ligands, and their receptors. These cumulative observations also provide an explanation for the rigidly controlled K1 levels in the mammalian fetus and the minimal hepatic stores in the adult.

apoptosis γ-carboxylation Gas6 Protein S receptor tyrosine kinases vitamin K1-dependent proteins. 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Dam H. Cholesterinstoffwechsel in Huhnereiern und Huhnchen. Biochem Z 1929; 215: 475–492.Google Scholar
  2. 2.
    Shearer MJ. Vitamin K. Lancet 1995; 345: 229–234.PubMedGoogle Scholar
  3. 3.
    Shearer MJ, McCarthy PT, Crampton OE, Mattock M. The assessment of human vitamin K status from tissue measurements. In: Suttie JW, ed. Current Advances in Vitamin K Research. New York: Elsevier 1988: 437–452.Google Scholar
  4. 4.
    Ferland G, Sadowski JA, O'Brien ME. Dietary induced sub-clinical vitamin K deficiency in normal human subjects. J Clin Invest 1993; 91: 1761–1768.PubMedGoogle Scholar
  5. 5.
    Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505–518.PubMedGoogle Scholar
  6. 6.
    Mann KG. The role of the membrane in the expression of the vitamin K-dependent enzymes. Arch Path Lab Med 1992; 116: 1330–1336.PubMedGoogle Scholar
  7. 7.
    Furie B, Furie BC. Molecular basis of vitamin K-dependent γ-carboxylation. Blood 1990; 75: 1753–1762.PubMedGoogle Scholar
  8. 8.
    Stenflo J. Contributions of Gla and EGF-like domains to the function of vitamin K-dependent coagulation factors. Crit Rev Eukaryot Gene Exp 1999; 9: 59–88.Google Scholar
  9. 9.
    Dahlback B, Hildebrand B, Malm J. Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem 1990; 265: 8127–8135.PubMedGoogle Scholar
  10. 10.
    Prieto AL, Weber JL, Tracy S, Heeb MJ, Lai C. Gas6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res 1999; 816: 646–661.PubMedGoogle Scholar
  11. 11.
    Manfioletti G, Brancolini C, Avanzi G, Schneider C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol Cell Biol 1993; 13: 4976–4985.PubMedGoogle Scholar
  12. 12.
    Vermeer C, Hendrix H, Daemen M. Vitamin K-dependent carboxylases from non-hepatic tissues. FEBS Lett 1982; 148: 317–320.PubMedGoogle Scholar
  13. 13.
    de Boer-van den Berg MA, Verstijnen CP, Vermeer C. Vitamin K-dependent carboxylase in skin. J Invest Dermatol 1986; 87: 377–380.PubMedGoogle Scholar
  14. 14.
    de Boer-van den Berg MA, Uitendaal MP, Vermeer C. Direct measurement of vitamin K-dependent enzymes in various isolated and cultured tumor and non-tumor cells. Mol Cell Biochem 1987; 75: 71–76.PubMedGoogle Scholar
  15. 15.
    Al-Mondhiry H, Wallin R. Synthesis of vitamin K-dependent proteins by cultured human tumor cells. Thromb Haemost 1989; 62: 661–666.PubMedGoogle Scholar
  16. 16.
    Hauschka PV, Haroon Y, Buchthal SD, Bell RG. Vitamin K-dependent processes in tumor cells. Haemostasis 1986; 16: 273–287.PubMedGoogle Scholar
  17. 17.
    Lai C, Lemke G. An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron 1991; 6: 691–704.PubMedGoogle Scholar
  18. 18.
    Lai C, Gore M, Lemke G. Structure, expression and activity of Tyro 3, a neural adhesion-related receptor tyrosine kinase. Oncogene 1994; 9: 2567–2578.PubMedGoogle Scholar
  19. 19.
    Mark MR, Scadden DT, Wang Z, Gu Q, Goddard A, Godowski PJ. RSE, a novel receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the brain. J Biol Chem 1994; 269: 10720–10728.PubMedGoogle Scholar
  20. 20.
    Taylor IC, Roy S, Yaswen P, Stampfer MR, Varmus HE. Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. J Biol Chem 1995; 270: 6872–6880.PubMedGoogle Scholar
  21. 21.
    O'Bryan JP, Frye RA, Cogswell PC, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991; 11: 5016–5031.PubMedGoogle Scholar
  22. 22.
    Rescigno J, Mansukhani A, Basilico C. Aputative receptor tyrosine kinase with unique structural topology. Oncogene 1991; 6: 1909–1913.PubMedGoogle Scholar
  23. 23.
    Janssen JWG, Schulz AS, Steenvoorden ACM, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene 1991; 11: 2113–2120.Google Scholar
  24. 24.
    Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS: Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ 1994; 5: 647–657.PubMedGoogle Scholar
  25. 25.
    Jia R, Hanafusa H. The proto-oncogene of v-eyk (v-ryk) is a novel receptor-type protein tyrosine kinase with extracellular Ig/GN-III domains. J Biol Chem 1994; 269: 1839–1844.PubMedGoogle Scholar
  26. 26.
    Edelman, GM, Crossin KL. Cell adhesion molecules: Implications for a molecular histology. Annu Rev Biochem 1991; 60: 155–190.CrossRefPubMedGoogle Scholar
  27. 27.
    Krueger NX, Saito H. A human transmembrane protein-tyrosine phosphatase, PTP γ, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrase. Proc Natl Acad Sci USA 1992; 89: 7417–7421.PubMedGoogle Scholar
  28. 28.
    Varnum BC, Young C, Elliot G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995; 373: 623–626.PubMedGoogle Scholar
  29. 29.
    Stitt TN, Conn G, Gore M, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661–670.PubMedGoogle Scholar
  30. 30.
    Crosier KE, Crosier PS. New insights into the control of cell growth; the role of the AxI family. Pathology 1997; 29: 131–135.PubMedGoogle Scholar
  31. 31.
    Lee WP, Liao Y, Robinson D, Kung HJ, Liu ET, Hung MC. Axl-gas6 interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol Cell Biol 1999; 19: 8075–8082.PubMedGoogle Scholar
  32. 32.
    Ling L, Kung HJ. Mitogenic signals and transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 1995; 15: 6582–6592.PubMedGoogle Scholar
  33. 33.
    Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 1996; 12: 471–480.PubMedGoogle Scholar
  34. 34.
    McCloskey P, Pierce J, Koski RA, Varnum B, Liu ET. Activation of the Axl receptor tyrosine kinase induces mitogenesis and transformation in 32D cells. Cell Growth Differ 1994; 5: 1105–1117.PubMedGoogle Scholar
  35. 35.
    O'Bryan JP, Fridell YW, Koski R, Varnum B, Liu ET. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem 1995; 270: 551–557.PubMedGoogle Scholar
  36. 36.
    Zhang QK, Boast S, de los Santos K, Begemann M, Goff SP. Transforming activity of retroviral genomes encoding Gag-Axl fusion proteins. J Virol 1996; 70: 8089–8097.PubMedGoogle Scholar
  37. 37.
    Neubauer A, Burchert A, Maiwald C, et al. Recent progress on the role of Axl, a receptor tyrosine kinase, in malignant transformation of myeloid leukemias. Leuk Lymphoma 1997; 25: 91–96.PubMedGoogle Scholar
  38. 38.
    Chen J, Carey K, Godowski PJ. dentification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 1997; 14: 2033–2039.PubMedGoogle Scholar
  39. 39.
    Burchert A, Attar EC, McCloskey P, Fridell YW, Liu ET. Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene 1998; 16: 3177–3187.PubMedGoogle Scholar
  40. 40.
    Besser D, Bromberg JF, Darnell JE Jr, Hanafusa H. A single amino acid substitution in the v-Eyk intracellular domain results in activation of Stat3 and enhances cellular transformation. Mol Cell Biol 1999; 19: 1401–1409.PubMedGoogle Scholar
  41. 41.
    Melaragno MG, Wuthrich DA, Poppa V, et al. Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein-coupled receptor agonists in rats. Circ Res 1998; 83: 697–704.PubMedGoogle Scholar
  42. 42.
    Fridell YW, Villa J Jr, Attar EC, Liu ET. Gas6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. J Biol Chem 1998; 273: 7123–7126.PubMedGoogle Scholar
  43. 43.
    Nakano T, Ishimoto Y, Kishino J, et al. Cell adhesion to phosphatidylserine mediated by a product of growth arrest-specific gene 6. J Biol Chem 1997; 272: 29411–29414.PubMedGoogle Scholar
  44. 44.
    Ishimoto Y, Ohashi K, Mizuno K, Nakano T. Promotion of the Uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6. J Biochem (Tokyo) 2000; 127: 411–417.Google Scholar
  45. 45.
    Nakano T, Kawamoto K, Higashino K, Arita H. Prevention of growth arrest-induced cell death of vascular smooth muscle cells by a product of growth arrest-specific gene, gas6. FEBS Lett 1996; 387: 78–80.PubMedGoogle Scholar
  46. 46.
    Bellosta P, Zhang Q, Goff SP, Basilico C. Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 1997; 15: 2387–2397.PubMedGoogle Scholar
  47. 47.
    Goruppi S, Ruaro E, Varnum B, Schneider C. Requirement of phosphatidylinositol 3-kinase-dependent pathway and Src for Gas6-Axl mitogenic and survival activities in NIH 3T3 fibroblasts. Mol Cell Biol 1997; 17: 4442–4453.PubMedGoogle Scholar
  48. 48.
    Allen MP, Zeng C, Schneider K, et al. Growth arrest-specific gene 6 (Gas6)/adhesion related kinase (Ark) signaling promotes gonadotropin-releasing hormone neuronal survival via extracellular signal-regulated kinase (ERK) and Akt. Mol Endocrinol 1999; 13: 191–201.PubMedGoogle Scholar
  49. 49.
    Goruppi S, Ruaro E, Varnum B, Schneider C. Gas6-mediated survival in NIH3T3 cells activates stress signaling cascade and is independent of Ras. Oncogene 1999; 18: 4224–4236.PubMedGoogle Scholar
  50. 50.
    O'Donnell K, Harkes IC, Dougherty L, Wicks IP. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: Evidence for a novel endothelial cell survival pathway. Am J Pathol 1999; 154: 1171–1180.PubMedGoogle Scholar
  51. 51.
    Grand RJA, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996; 313: 353–368.PubMedGoogle Scholar
  52. 52.
    Altieri DC. Xa receptor EPR-1. FASEB J 1995; 9: 860–865.PubMedGoogle Scholar
  53. 53.
    Nagata K, Ohashi K, Nakano T, et al. Identification of the product of growth arrest-specific Gene 6 as a common ligand for Axl, Sky and Mer receptor tyrosine kinases. J Biol Chem 1996; 271: 30022–30027.PubMedGoogle Scholar
  54. 54.
    Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 1996; 271: 9785–9789.PubMedGoogle Scholar
  55. 55.
    Joseph DR, Baker ME. Sex hormone-binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin and Drosophila crumbs protein. FASEB J 1992; 6: 2477–2481.PubMedGoogle Scholar
  56. 56.
    Tanabe K, Nagata K, Ohashi K, Nakano T, Arita H, Mizuno K. Roles of gamma-carboxylation and a sex hormone-binding globulin-like domain in receptor-binding and in biological activities of Gas6. FEBS Lett 1997; 408: 306–310.PubMedGoogle Scholar
  57. 57.
    Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. Requirement of γ-carboxyglutamic acid residues for the biological activity of Gas6: Contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997; 323: 387–392.PubMedGoogle Scholar
  58. 58.
    Nakano T, Kishino J, Arita H. Characterization of a high-affinity and specific binding site for Gas6. FEBS Lett 1996; 387: 75–77.PubMedGoogle Scholar
  59. 59.
    Nyberg P, He X, Hardig Y, Dahlback B, Garcia de Frutos P. Stimulation of Sky tyrosine phosphorylation by bovine protein S domains involved in the receptor-ligand interaction. Eur J Biochem 1997; 246: 147–154.PubMedGoogle Scholar
  60. 60.
    Nyberg P, Xuhua H, Hardig Y, Dahlback B, Garcia de Frutos, P. Stimulation of phosphorylation by bovine protein S: Domains involved in the receptor-ligand interaction. Eur J Biochem 1997; 246: 147–154.PubMedGoogle Scholar
  61. 61.
    Fair DS, Marlar RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986; 67: 1168–1171.PubMedGoogle Scholar
  62. 62.
    Phillips DJ, Greengard JS, Fernandez JA, et al. Protein S, an antithrombotic factor, is synthesized and released by neural tumor cells. J Neurochem 1993; 61: 344–347.PubMedGoogle Scholar
  63. 63.
    Benzakour O, Formstone C, Rahman S, et al. Evidence for a protein S receptor(s) on human vascular smooth muscle cells. Biochem J 1995; 308: 481–485.PubMedGoogle Scholar
  64. 64.
    Wimmel A, Rohner I, Ramaswamy A, et al. Synthesis and secretion of the anticoagulant protein S and coexpression of the Tyro3 receptor in human lung carcinoma cells. Cancer 1999; 86: 43–49.PubMedGoogle Scholar
  65. 65.
    Lu Q, Gore M, Zhang Q, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999; 298: 723–728.Google Scholar
  66. 66.
    Neubauer A, Fiebeler A, Graham DK, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994; 84: 1931–1941.PubMedGoogle Scholar
  67. 67.
    Faust M, Ebensperger C, Schulz, et al. The murine ufo receptor: Molecular cloning, chromosomal localization and in situ expression analysis. Oncogene 1992; 7: 1287–1293.PubMedGoogle Scholar
  68. 68.
    Craven RJ, Xu H, Weiner TM, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995; 60: 791–797.PubMedGoogle Scholar
  69. 69.
    Ito T, Ito M, Naito S, et al. Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 1999; 9: 563–567.PubMedGoogle Scholar
  70. 70.
    Tsou AP, Wu KM, Tsen TY. Parallel hybridization analysis of multiple protein kinase genes: Identification of gene expression patterns characterstics of human hepatocellular carcinoma. Genomics 1998; 50: 331–340.PubMedGoogle Scholar
  71. 71.
    Jacob AN, Kalapurakal J, Davidson WR, et al. A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a modified differential display PCR are overexpressed in metastatic prostatic carcinoma cell line DU145. Cancer Detect Prev 1999; 23: 325–332.PubMedGoogle Scholar
  72. 72.
    Rochlitz C, Lohri A, Bacchi M, et al. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999; 13: 1352–1358.PubMedGoogle Scholar
  73. 73.
    Quong RYY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in normal and transformed melanocytes. Melanoma Res 1994; 4: 313–319.PubMedGoogle Scholar
  74. 74.
    Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in soft tissue tumors. Ann Surg Oncol 1994; 1: 18–27.PubMedGoogle Scholar
  75. 75.
    Ohashi K, Nagata K, Toshima J, et al. Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6. J Biol Chem 1995; 270: 22681–22684.PubMedGoogle Scholar
  76. 76.
    Crosier PS, Freeman SA, Orlic D, Bodine DM, Crosier KE. The Dtk receptor tyrosine kinase, which binds protein S, is expressed during hematopoiesis. Exp Hematol 1996; 24: 318–323.PubMedGoogle Scholar
  77. 77.
    Ohashi K, Mizuno K, Kuma K, Miyata T, Nakamura T. Cloning of the cDNA for a novel receptor tyrosine kinase, Sky, predominantly expressed in brain. Oncogene 1994; 9: 699–705.PubMedGoogle Scholar
  78. 78.
    Crosier PS, Hall LR, Vitas MR, Lewis PM, Crosier KE. Identification of a novel receptor tyrosine kinase expressed in acute myeloid leukemic blasts. Leuk Lymphoma 1995; 18: 443–449.PubMedGoogle Scholar
  79. 79.
    Taylor IC, Roy S, Yaswen P, Stampfer MR, Varmus HE. Mouse mammary tumors express elevated levels of RNA encoding the murine homology of SKY, a putative receptor tyrosine kinase. J Biol Chem 1995; 270: 6872–6880.PubMedGoogle Scholar
  80. 80.
    Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology 1997; 65: 195–203.PubMedGoogle Scholar
  81. 81.
    Taylor IC, Roy S, Varmus HE. Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation. Oncogene 1995; 11: 2619–2626.PubMedGoogle Scholar
  82. 82.
    Li R, Chen J, Hammonds G, et al. Identification of Gas6 as a growth factor for human Schwann cells. J Neurosci 1996; 16: 2012–2019.PubMedGoogle Scholar
  83. 83.
    Loeser RF, Varnum BC, Carlson CS, et al. Human chondrocyte expression of growth-arrest-specific gene 6 and the tyrosine kinase receptor axl: Potential role in autocrine signaling in cartilage. Arthritis Rheum 1997; 40: 1455–1465.PubMedGoogle Scholar
  84. 84.
    Nakano T, Higashino K, Kikuchi N, et al. Vascular smooth muscle cell-derived, Gla-containing growth-potentiating factor for Ca(2+)-mobilizing growth factors. J Biol Chem 1995; 270: 5702–5705.PubMedGoogle Scholar
  85. 85.
    Nakamura YS, Hakeda Y, Takakura N, et al. Tyro 3 receptor tyrosine kinase and its ligand, Gas6, stimulate the function of osteoclasts. Stem Cells 1998; 16: 229–238.PubMedGoogle Scholar
  86. 86.
    Bellosta P, Costa M, Lin DA, Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 1995; 15: 614–625.PubMedGoogle Scholar
  87. 87.
    Song Z, Steller H. Death by design: Mechanism and control of apoptosis. Trends Cell Biol 1999; 9: M49–52.PubMedGoogle Scholar
  88. 88.
    Brill A, Torchinsky A, Carp H, Toder V. The role of apoptosis in normal and abnormal embryonic development. Assist Reprod Genet 1999; 16: 512–519.Google Scholar
  89. 89.
    Leach AP. Apoptosis: Molecular mechanism for physiologic cell death. Clin Lab Sci 1998; 11: 346–349.PubMedGoogle Scholar
  90. 90.
    Warner HR. Apoptosis: A two-edged sword in aging. Anticancer Res 1999; 19: 2837–2842.PubMedGoogle Scholar
  91. 91.
    Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signaling. Biochem J 1998; 333: 471–490.PubMedGoogle Scholar
  92. 92.
    Wymann MP, Pirola L. Structure and function of phosphor-inositide 3-kinases. Biochim Biophys Acta 1998; 1436: 127–150.PubMedGoogle Scholar
  93. 93.
    Datta SR, Dudek H, TaoX, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231–241.PubMedGoogle Scholar
  94. 94.
    Fridell YW, Jin Y, Quilliam LA, et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 1996; 16: 135–145.PubMedGoogle Scholar
  95. 95.
    Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-KB. Mol Cell Biol 1999; 19: 1171–1181.PubMedGoogle Scholar
  96. 96.
    Zong C, Yan R, August A, Darnell JE Jr, Hanafusa H. Unique signal transduction of Eyk: Constitutive stimulation of the Jak-Stat pathway by an oncogeneic receptor-type tyrosine kinase. Embo J 1996; 15: 4515–4525.PubMedGoogle Scholar
  97. 97.
    Olson MF, Marais R. Ras protein signalling. Semin Immunol 2000; 12: 63–73.PubMedGoogle Scholar
  98. 98.
    Rebollo A, Martinez AC. Ras proteins: Recent advances and new functions. Blood 1999; 94: 2971–2980.PubMedGoogle Scholar
  99. 99.
    Shearer MJ, Rahim S, Barkhan P, Stimmler L. Plasma vitamin K1 in mothers and their newborn babies. Lancet 1982; ii: 460–463.Google Scholar
  100. 100.
    Israels LG, Israels ED, Saxena SP. The riddle of vitamin K1 deficit in the newborn. Semin Perinatol 1997; 21: 90–96.PubMedGoogle Scholar
  101. 101.
    Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122–140.PubMedGoogle Scholar
  102. 102.
    Howe AM, Webster WS. The warfarin embryopathy: A rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology 1992; 46: 379–390.PubMedGoogle Scholar
  103. 103.
    Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: Clues to the mechanism of teratogenicity of coumarin derivatives. Am J Hum Genet 1987; 41: 566–583.PubMedGoogle Scholar
  104. 104.
    Wulfsberg EA, Curtis J, Jayne CH. Chondrodysplasia punctata: Aboy with X-linked recessive chondrodysplasia punctata due to an inherited X-Y translocation with a current classification of these disorders. Am J Med Genet 1992; 43: 823–828.PubMedGoogle Scholar
  105. 105.
    Franco B, Meroni G, Parenti G, et al. A cluster of sulfatase genes on Xp22.3: Mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell 1995; 81: 15–25.PubMedGoogle Scholar
  106. 106.
    Saxena S, Fan T, Li M, Israels ED, Israels LG. A novel role for vitamin K1 in a tyrosine phosphorylation cascade during chick embryogenesis. J Clin Invest 1997; 99: 602–607.PubMedGoogle Scholar
  107. 107.
    McCloskey P, Fridell Y-W, Attar E, et al. Gas6 mediates adhesion of cells expressing the receptor tyrosine kinase Axl. J Biol Chem 1997; 272: 23285–23291.PubMedGoogle Scholar
  108. 108.
    Hilgard P. Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer 1977; 35: 891–892.PubMedGoogle Scholar
  109. 109.
    Hilgard P, Maat B. Mechanism of lung tumor colony reduction caused by coumarin anticoagulation. Eur J Cancer 1979; 15: 183–187.PubMedGoogle Scholar
  110. 110.
    Collucci M, Deliani F, Vihi G, et al. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Biochem Pharmacol 1983; 32: 1689–1691.PubMedGoogle Scholar
  111. 111.
    Goeting N, Trotter GA, Cooke T, Kirkham N, Taylor I. Effect of warfarin on cell kinetics, epithelial morphology and tumor incidence in induced colorectal cancer in the rat. Gut 1985; 26: 807–815.PubMedGoogle Scholar
  112. 112.
    Fasco MJ, Eagen GE, Wilson AC, Gierthy JF, Lincoln DL. Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum. Cancer Res 1988; 48: 6504–6509.PubMedGoogle Scholar
  113. 113.
    Israels LG, Walls GA, Ollmann DJ, Friesen E, Israels ED. Vitamin K as a regulator of benzo(a)pyrene metabolism, mutagenesis, and carcinogenesis. J Clin Invest 1983; 71: 1130–1140.PubMedGoogle Scholar
  114. 114.
    Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 1999; 91: 22–36.PubMedGoogle Scholar
  115. 115.
    Michaels L. Cancer incidence and mortality in patients having anticoagulant therapy. Lancet 1964; ii: 832–835.Google Scholar
  116. 116.
    He X, Shen L, Malmborg AC, Smith KJ, Dahlback B, Linse S. Binding site for C4b-binding protein in Vitamin K-dependent protein S fully contained in carboxy-terminal laminin-G-type repeats. A study using recombinant factor IX-protein S chimeras and surface plasmon resonance. Biochemistry 1997; 36: 3745–3754.PubMedGoogle Scholar
  117. 117.
    van Wijnen M, Stam JG, Chang GT, et al. Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain. Biochem J 1998; 330: 389–396.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • S. P. Saxena
    • 1
  • E. D. Israels
    • 2
  • L. G. Israels
    • 3
  1. 1.Lovelace Respiratory Research InstituteAlbuquerqueNew Mexico
  2. 2.Department of PediatricsUniversity of ManitobaWinnipegCanada
  3. 3.The Manitoba Institute of Cell BiologyUniversity of ManitobaWinnipegCanada

Personalised recommendations